Integrated Ocular Safety Summary Of Mirvetuximab Soravtansine From Four Clinical Trials In Patients With Folate Receptor Alpha (Frα)-Positive Recurrent Ovarian Cancer

Published 2024 - 42nd Congress of the ESCRS

Reference: FP15.01 | Type: Free paper | DOI: 10.82333/50r8-gh93